| 3i
plc Peter Gardner, Deputy Head of Communications Investments Sabine Kaiser, Investment Director Healthcare 3i brings capital, knowledge and connections to the creation and development of businesses around the world. It invests in a wide range of opportunities from start-ups to buy-outs and buy-ins, focusing on businesses with high growth potential and strong management. 3i invests in businesses across three continents through local investment teams in Europe, Asia Pacific and the USA. To date, 3i has invested over £14.5 billion (including co-investment funds). In the 12 months to 31March 2002, an average of £4.1 million (including co-investment funds) was invested each working day. In the 12 months to 31 March 2002, 3i invested £548m (including co-investment funds) in 361 technology businesses. 3i makes technology investments in a broad range of sectors including Communications, Healthcare and Software & Internet. The portfolio includes businesses at all stages of development. At 31 March 2002, 3i's technology portfolio was valued at £1.7 billion and included over 800 businesses. |
 |
| Apax
Partners Apax Partners is one of the world's leading private
equity investment groups dedicated to high performance, entrepreneurial
businesses. The group advises a number of Investment Pools with
an accumulated total of € 12 billion and pursues a balanced
equity portfolio strategy, investing in companies at all stages
of development from start-up to buy-out. The group focuses primarily
on six industry sectors: Telecommunications, Information Technology,
Media, Healthcare &Biotechnology, Retail & Consumer Products
and Financial Services. For further information on Apax Partners, visit www.apax.com. |
 |
| Allianz
Capital Partners Profile to follow shortly. |
 |
| Allianz
Venture Partners Allianz Venture Partners (AVP) is the Corporate Ventures subsidiary of Allianz Group, one of the world's leading financial institutions with over 700 group companies active in virtually all areas of the financial services industry. Allianz is represented in more than 70 countries around the globe with assets of more than USD 1 trillion under management. Allianz Venture Partners acts as a global investor
in new business opportunities within the financial services industry
as well as in related enabling technology providers with high growth
potential. |
|
| Biotechnology
Investment Today Biotechnology Investment Today is a quarterly review journal for stakeholders in the biotechnology industry. The magazine covers therapeutics and technology companies and markets as well as critical operational and financing issues that directly affect company and shareholder value. Topics covered in recent issues include: Cardiovascular
Therapeutics, RNAi, Pharmacogenomics, M&A, Capital Markets,
NIH and Pathways to Market. Biotechnology Investment Today is supported by a global seminar and investor network series with events held regularly in the US and Europe. Subjects covered in 2002/2003 include: Good Governance, Private Equity, Investor Relations, Biotech-Pharma Partnering and Clinical Trials and Approvals Management. |
Carlyle
Europe Venture Partners The next generation internet, we believe, will lead to unprecedented value creation opportunities. Bandwidth expansion, everywhere connectivity, flexible networks, distributed and ubiquitous intelligence, and the inter-connectivity of devices will alter the face of communications as we know it. The Carlyle Europe Venture Partners [CEVP] is one of
the largest venture capital funds focused on Europe. Europe will
experience unprecedented opportunities. The UK and the continent
are already beginning to enjoy the benefits of regulatory liberalization,
the emergence of common standards and the growth and mobility of
capital. |
 |
| Doughty
Hanson Technology Ventures Doughty Hanson & Co is an investor in three distinct asset classes: Private Equity, Real Estate, Technology Ventures. Doughty Hanson & Co is one of Europe's largest independent private equity fund managers. Operating Private Equity Funds for Europe and North America, a European Real Estate Fund and a European Technology Ventures Fund, Doughty Hanson & Co has unrivalled breadth of expertise. With offices across Europe and in the US, Doughty Hanson & Co has over 50 investment professionals managing €5bn of fund commitments. The Doughty Hanson & Co Group provides investment advisory services solely to a limited number of private funds. The opportunity to invest in those funds in turn is offered only to a limited number of sophisticated investors and not to the public. Neither the Doughty Hanson & Co Group's advisory services nor the funds it advises are offered through its website. Doughty Hanson & Co Managers Limited is regulated in the UK by The Financial Services Authority. |
 |
| Draper
Fisher Jurvetson Draper Fisher Jurvetson is the leader in start-up venture capital, having invested in over 150 high-tech companies. In the majority of cases, we are the lead investor for a company's first round of financing. We focus on information technology businesses with enormous market potential. Our role is to help entrepreneurs achieve their maximum potential through team building, partnerships, advice and support, as well as investments. By pursuing a people-focused approach to venture capital investing, we continue to fund entrepreneurs with the energy, vision, experience, and desire to build great companies. |
 |
| Earlybird
Venture Capital Earlybird provides capital, know-how, management support and a large network of industry experts to selected European and North American new technology enterprises and innovative entrepreneurs. Its strategy is to be among the first venture investors in technology companies that seek to create new markets. Earlybird currently manages three funds totalling US $ / Euro 300 million in committed capital. Its investment focus lies on information technology, communications, healthcare and convergent technologies. With offices in Europe (Hamburg, Munich) and the US (Palo Alto), Earlybird is well positioned to take advantage of international opportunities and to assist its portfolio companies to gain access to the international market place and financial resources. Earlybird´s investment professionals have extensive finance and start-up operating experience and actively support portfolio companies. In addition, a network of experienced industry specialists serves on the advisory board and assists Earlybird and its portfolio companies in providing strategic advice and operational support. |
 |
| ET
Capital Limited ETCapital Limited was set up in 1992 as an investor in high growth businesses based in southern England. Since 1998, ETCapital has invested QTP, a specialist zero-stage technology fund, focused on the globally significant cluster of science based businesses around Cambridge, Oxford and London. prior to that it managed what is now the HSBC UK Enterprise Fund for East Anglia & the Home Counties investing in early stage businesses, both technology and non-technology, based in East Anglia and the northern Home Counties. "All of us at ETCapital are focused on liberating the talent of the entrepreneurs we back. We want to help them build great technology businesses that are globally competitive and which generate the strongest possible returns for all shareholders. We believe that we have to 'make the difference' in the businesses we back: making connections, providing advice and guidance based on the experience of having invested in, between us, over fifty early stage businesses - as well as simply being there to listen." - Martin Rigby |
 |
| EXTOREL
Private Equity Advisors GmbH EXTOREL Private Equity Advisers is one of the leading German management companies for Fund of Funds in the Private Equity industry. The investment programmes are especially tailored for different investor groups like wealthy individuals or institutional investors. The team of EXTOREL Private Equity Advisers has long lasting experience not only in the investment in Venture Capital Funds but also in direct private equity investments. EXTOREL Private Equity Advisers acts also as family office for its main share holder and has about 500 million Euros under management. |
 |
| Intel
Capital Europe / Israel Intel Capital, Intel's strategic investment program began in the early 1990s and initially invested in PC- and chip-related technologies. Today, Intel Capital invests in companies to establish innovative technologies, help develop industry standards, drive Internet growth, and advance computing platforms in support of Intel's strategic interests. One of the largest corporate venture investing programs in the technology sector, Intel Capital's investment portfolio includes around 450 technology and related companies worldwide and is valued at approximately US$1 billion. The program typically takes small, minority stakes - generally less than US$10 million. Intel Capital also oversees the acquisition of companies that help Intel enter new business areas or that can strengthen existing Intel businesses. Intel's worldwide presence enables Intel Capital to engage with and invest in companies around the world who are developing leading-edge technology. This also helps Intel understand the evolving usage patterns and requirements of technology across many different cultures and languages. |
 |
| LGT
Capital Partners LGT Capital Partners is one of Europe’s leading private equity and hedge fund investors and fund of funds managers, with over EUR 1.8bn in private equity assets and over EUR 800m in hedge funds on a global basis. LGT Capital Partners acts both as principal investor and investment manager, with clients investing alongside the team’s own capital. This guarantees a perfect alignment of client's and team's interests. As a principal investor, LGT Capital Partners’ primary objective is to achieve superior risk-adjusted returns by accessing and actively investing in the most promising private equity and hedge fund investment opportunities worldwide. Among other vehicles, LGT Capital Partners’ dedicated team of over 35 alternative investment professionals (with 14 nationalities represented) is responsible for the investment management of two investment companies both listed on the SWX Swiss Exchange and on the Luxembourg stock exchange since 1997: Castle Private Equity and Castle Alternative Invest. LGT Capital Partners’ list of clients includes Axa, Swiss Life, McKinsey & Company, the Princely family of Liechtenstein, and other sophisticated institutional and private investors in Germany and Austria. LGT Capital Partners works with clients as partners, sharing insights and ideas from principal to principal. Over the years, the team has built substantial expertise and an extensive network in the global private equity and hedge fund industries, and is known as a sophisticated, long-term investor with an outstanding track record. LGT Capital Partners AG is operating as an autonomous legal entity in Switzerland. For more information: aim@lgt.com or telephone: +41 55 415 9 415 |
 |
| MIT
Artificial Intelligence Laboratory The Artificial Intelligence Laboratory has been an active entity at MIT in one form or another since at least 1959. Our goal is to understand the nature of intelligence and to engineer systems that exhibit intelligence. We are an interdisciplinary laboratory of over 200 people that spans several academic departments and has active projects ongoing with members of every academic school at MIT. Our intellectual goal is to understand how the human mind works. We believe that vision, robotics, and language are the keys to understanding intelligence, and as such our laboratory is much more heavily biased in these directions than many other Artificial Intelligence laboratories. |
 |
| MPM
Capital MPM Capital is the manager for the BioVentures and BioEquities family of funds that are invested in select healthcare companies in the US and in Europe. We are dedicated to delivering exceptional returns to our investors by using our world class research and investment management capabilities to invest in new and emerging healthcare companies. We currently manage in excess of $1 billion of committed capital through three investment vehicles, BioVentures I, MPM BioVentures II and the MPM BioEquities Fund. Uniquely positioned as a global firm with presences in both the United States and Europe, our focus is on biotechnology, biopharmaceuticals and medical devices. We invest at all stages of development in the healthcare space: with private equity investments from $5 - $50 million per portfolio company, we seek to partner with exceptional entrepreneurs and to help finance and build companies that will become industry leaders. On the public side, we focus on identifying emerging small and mid-cap biotech winners while actively managing for risk and volatility. MPM BioVentures is led by a cross-functional partner team of industry leaders with expertise in private and public equity investing as well as direct operating experience in product development, clinical medicine and biomedical research. We have established a world-class Medical and Scientific Advisory Board consisting of recognized leaders in the healthcare field. The MPM BioVentures team includes over 20 professionals in three locations, Boston, San Francisco and Munich. Our corporate presence in centers of innovation allows us to monitor technical breakthroughs and swiftly respond to market opportunities. MPM Capital is devoted to investing in healthcare, primarily in biotechnology and biopharmaceuticals, and secondarily in medical devices and technologies. We look to identify companies with exceptional growth potential and are dedicated to helping support these companies through to the point where demonstrable value has been built. Detailed evaluation of the business model and the technical capabilities enables us to choose our investments appropriately and to assist those portfolio companies once we have invested. We typically take the lead role in the financing, and often anchor a wider syndicate of investors. Although we seek to be significant shareholders, we are comfortable taking minority positions. The funds have a 10-year life enabling us to be long-term investors. The BioVentures family of funds is one of the largest dedicated healthcare venture capital funds focused on private healthcare companies without limitation to specific stage of development. We actively manage our portfolio of investments, providing strategic support, business development and financial backing. MPM BioEquities is led by top-rated fund manager, Kurt von Emster. MPM BioEquities is a public-market focused biotech fund with the ability to invest in late stage private financings. The fund supports companies throughout their public lives and as such provides an excellent complement to MPM BioVentures. The seamless integration of private and public financial products benefits our industry and facilitates the growth of highly promising companies. |
| Nomura
International plc Nomura's Healthcare Private Equity team is one of the
leading global providers of finance to emerging healthcare companies.
The team is part Nomura's Merchant Banking Division based in London.
Nomura is Japan's largest securities firm and a leading global investment
bank. In the last four years the Healthcare and Technology Private
Equity teams have invested close to $500 million in over 70 companies
in the US and Europe. |
 |
| Partech
International Partech International, founded in 1982, is an international venture capital firm with offices in San Francisco, Paris and Tel Aviv. The firm currently manages approximately $850 million in early stage venture, mid stage venture and public investments. Partech International differentiates itself in three important ways:
Partech International’s venture funds draw capital
from a broad base of world-class institutional investors, including
AGF Allianz, AXA, Bell Atlantic, Asset Management, Crédit
Agricole, GTE, IBM Pension, JP Morgan Asset Management, Liverpool
Victoria, Merril Lynch, Swiss Life, Vontobel Bank. The partnership, with offices in Paris, San Francisco and Tel Aviv operates as a unified team, and is organized by industry sector, rather than geography. Thus, partners from those offices participate in industry research and investment decisions. |
 |
| PolyTechnos
Venture-Partners PolyTechnos Venture-Partners GmbH (“PolyTechnos”) nurtures revolutionary technologies and guides exceptional entrepreneurs in growing their businesses. Founded in 1998, PolyTechnos focuses on start-up and early stage, high-growth companies in the areas of Life Sciences, IT, Communications, Materials & Components, and particularly their interfaces. Geographical focus: Germany and other European countries. PolyTechnos’ Investment Team consists of highly experienced industry leaders. Its team composition combines deep technological understanding, senior executive experience and a wide international network. PolyTechnos provides value-added services to the portfolio companies of its advised funds. This includes strategy formulation, top-level industry networks, intellectual property positioning, corporate governance, and human resource development. With Headquarters in Munich/Germany, PolyTechnos has additional offices in Frankfurt/Germany and Brussels/Belgium. |
 |
| Schroder
Salomon Smith Barney Citigroup Corporate & Investment Bank successfully combines a bulge-bracket investment bank – Schroder Salomon Smith Barney (SSSB) – with a world class commercial bank – Citibank. Citigroup is the world’s largest global financial services company with a market capitalisation of approximately $250bn. Its businesses provide a broad range of financial products and services to almost 150 million consumers and corporate customers spanning five continents and more than 100 countries. Increasingly, corporate and other institutional clients want a total solution for their financial requirements (one-stop shopping). Citigroup, with the global network of its commercial bank, is able to combine its balance sheet strength with the investment banking expertise of SSSB and delivers just this. Our record core income of $14.14bn for the year 2000 made us one of the most profitable companies in the world. International Financing Review named Citigroup “Bank of the Year” for the second year in a row claiming “in the recent history of investment banking and capital markets, no firm has come close to demonstrating quite as much year-on-year progress in such a visibly compelling way. |
 |
| Siemens
Venture Capital Siemens Venture Capital (SVC) is the corporate venture
organization |
 |
| St.
John's Innovation Centre Ltd Located on the Innovation Park developed by St John's College, University of Cambridge, the Innovation Centre provides business support and accommodation for early stage knowledge based companies. The Centre differentiates itself from other property developments by:-
The Innovation Centre was opened in 1987, and as well as providing business advice to tenants, offers them flexible accommodation in leasing terms and the possibility to share communal facilities including conference rooms and a restaurant. Centre tenants are aspirational start-up firms operating in a wide range of leading-edge technologies including neural networks, workflow management software, multimedia, fixed and mobile telecommunications, cryotechnology, biomedical imaging, lasers, chromatography, data communications, instrumentation, films and, increasingly, biotechnology. |
| SWX
Swiss Exchange The SWX Swiss Exchange is one of the world’s leading and most technologically advanced securities exchanges. In 1996, floor-based trading in Switzerland was supplanted by electronic trading. This fully automated trading, clearing and settlement system remains unique in the world. At the click of a mouse, an order is executed, cleared, paid for and confirmed. The SWX Swiss Exchange offers its customers first-rate securities exchange services and a broad range of investment products. The SWX Swiss Exchange provides innovative, international companies with access to the Swiss capital market. A public offering in one of its segments affords issuing companies a high degree of global visibility among investors, especially those with a heightened interest in certain sectors. An IPO in Switzerland represents an attractive means of obtaining equity financing especially for companies from the life science and IT sectors as well as the micro- and nanotechnology industries. E-mail: gbe-kae@swx.com |
 |
| Target
Partners Target Partners is a venture capital partnership with a single, focused mission: to help entrepreneurs build highly successful companies. Our strategy succeeds through a unique combination of teamwork, excellent contacts, experience, professionalism, and a strong capital base. Collectively the Target Partners team has over 40 years of experience in the information technology and venture capital industries. We have developed and marketed products and services, hired people and met payrolls, raised financing, made investments and taken many companies public. This experience, much of it obtained in the US market, is placed fully at the disposal of our portfolio companies to help ensure their competitive success. With over € 112 million under management, Target Partners is one of the best-capitalized "early stage" venture firms in Germany. As a result, we are able to set aside capital for multiple rounds of funding, should these be necessary for the success of our portfolio companies. |
 |
| T-Venture T-Venture is a 100% operating arm of Deutsche Telekom AG and was founded in 1997. It is one of Europe’s leading corporate venture capital companies with a total fund volume of €500 million. T-Venture is represented by its offices and partners in the major technology and innovation centers of Europe, the USA, Asia and Israel. It draws its strength from being part of the global network of the world’s third largest telecommunications company. T-Venture is one of the key investors in the T.I.M.E.S. sectors (Telecommunications, IT, Multimedia, Entertainment/e-Business, Security) and focuses on companies in the start-up or expansion phase that possess innovative products and business models, as well as real potential for growth. |
 |
| Viventures
Partners Viventures Partners, a global management company for venture capital which recently closed its second fund with 638 million euros, invests in early stage companies focused on the information technology and telecommunication sectors, primarily on telecom & datacom infrastructures, applications and middleware for telecom (mobile and fixed), and optical components and systems. Viventures invests on a global basis, with at least 50% dedicated to Europe, offering companies not only financial commitment but also the technology, business and international expertise of its experienced partners as well as an extensive worldwide network of resources, including relationships with its global, blue chip investors. In most cases, we invest in the early institutional rounds of funding. In all cases we work very closely with our Limited Partners to forge close business relationships with our portfolio companies. These Limited Partners include over 30 industrial and financial enterprises from Europe, the US and Asia who are global leaders in their respective businesses (technology, telecommunications, media and entertainment, and financial services). This unique mix of investors, present and active on an international scale, reflects the fund's global character and contributes to the long-term financial and business success of the fund's portfolio companies. Viventures Partners is headquartered in Paris, France and has offices in the UK (Reading), the US (San Francisco), Asia (Singapore) and in Sweden (Stockholm) through CGT Equity Advisors, independent advisors to Viventures Partners for the Nordic Region. |
 |
| Warburg
Pincus Warburg Pincus LLC is a major global private equity investment firm. Over the past 30 years, it has invested in more than 460 companies worldwide. Warburg Pincus ist currently managing nearly $10 billion of investments, with approximately $6 billion available for investment. |
 |